Swiss Biotech Day, Basel

SynDermix attends Swiss Biotech Day 2019, the annual get-together of the Swiss biopharmaceutical industry.



The management of SynDermix announced today that the Company is attending Swiss Biotech Day 2019. Organised by the Swiss Biotech Association, of which SynDermix is a member, the event takes place in Basel each year. It is the annual get-together of the Swiss biopharmaceutical industry, which offers established and start-up companies in the biotech arena the opportunity to present their innovations, attend focused panel discussions and engage in scheduled partnering meetings throughout the course of the event. SynDermix will be represented by Dr Carlos Camozzi (Director of Clinical and Regulatory Development), Dr Konstantinos Efthymiopoulos (Director of Non-Clinical and Business Development) and Dr Anastasia Mantalidi (Director of Manufacturing, IP & QM). “We are excited to return to Swiss Biotech Day for a second year, to share the progress we have made in our drug pipelines and reconnect with industry professionals whose interests overlap with those of SynDermix.” said Dr Anastasia Mantalidi on attending the event. Last year, the Chief Executive Officer of SynDermix, Mr Dieter Hemmer, presented the company’s strategy and technologies during the “Emerging Companies” session of Swiss Biotech Day. This year, SynDermix hopes to further connect with industry professionals and explore new business development opportunities.


About SynDermix AG
SynDermix AG is a Swiss developer of innovative health technologies funded by private investors. The Company focuses on the development of effective and safe treatments that meaningfully respect patient convenience and address important unmet medical needs.

SynDermix has built a diversified portfolio of innovative assets which correspond to three distinct proprietary technology platforms: smart medical devices based on digital acoustic modulation; drugs and medical devices based on a topical nitric oxide-releasing formulation; and drug candidates based on a recombinant plant lectin. Its business model is to a large extent virtual, driven by a strategy of in-licensing, outsourcing and out-licensing; the Company enters into strategic partnerships with third parties for the acquisition, development and commercialisation of a robust portfolio of assets with high innovation value and commercial potential. For more information please visit:


SynDermix Management AG
Julian Heinrich

+41 44 366 40 16